Advances in Immunotherapy in Metastatic Non–Small Cell Lung Cancer | Supplements And Featured Publications

Expert Perspectives on Promising Data Discussed at the Immunotherapy Non–Small Cell Lung Cancer Workshop

January 11, 2021

Sarah Goldberg, MD, MPH, discusses a network meta-analysis of randomized trials of chemoimmunotherapy with in patients with advanced disease, data suggest that certain populations with high, and perhaps low, PD-L1 expression may not require combination therapy, which would minimize adverse event potential.

Advances in Immunotherapy in Metastatic Non–Small Cell Lung Cancer

January 08, 2021

Non-small cell lung cancer is the most common histologic subtype of the disease, accounting for approximately 85% of cases. The recognition of targetable gene alterations and immune response has resulted in rapid changes to the therapeutic spectrum for NSCLC in recent years.

x